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Abstract
According to a statement from the U.S. Centers for Disease Control and Prevention,
between 2000 and 2017, approximately 700,000 people died from drug overdoses in the United
States. Approximately 128 persons lose their life each day from an opioid overdose. The data for
this study were collected by the vice president of operations at the study site from a preexisting
database for 2019 and 2020. The participants were inpatient patients, 18 and older, both male and
female, and were from all ethnicities. The study facility was located in Western New York and
offered a 30-bed inpatient treatment center with 24-hour care for individuals suffering from
opioid use disorder (OUD). The healthcare team consisted of physicians, nurses, behavioral
therapists, peer support specialists, and discharge planners. The objective of this descriptive,
retrospective project was to investigate the following research questions: Research Question 1:
During inpatient MAT treatment for OUD, is there a difference between treatments using
buprenorphine/naloxone and those using Vivitrol in the length of stay of patients? Research
Question 2: Is there a difference in these two MAT (buprenorphine and Vivitrol) outcomes when
controlling for demographic variables of patients with OUD? Research Question 3: Does
ethnicity moderate the relationship in MAT types and the length of stay among patients with
OUD? The ability to implement the MAT program and experience the benefits is rewarding to
the health care team, the patients, and their families. Further education is needed to assist in the
fight against this deadly epidemic.
Keywords: Opioid use disorder, retrospective study, ethical considerations,
demographics, economic impact, buprenorphine, and Vivitrol.
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Chapter 1: Introduction
According to a statement from the U.S. Centers for Disease Control and Prevention
(CDC, 2018b), between 2000 and 2017, approximately 700,000 people died from drug overdoses
in the United States. Specifically, 68% of these deaths, or about 70,200 persons, were opioidrelated and occurred in 2017. About 128 persons die each day from an opioid overdose (CDC,
2018b). Opioids—codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone,
oxycodone—are primarily used as analgesics. The United States Department of Health and
Human Services (HHS; n.d.) has considered that opioid-related deaths are a national emergency
crisis that fundamentally influences issues in public health and social and government finances
due to increases in health care costs, nearly $80 billion per year, and opioid use disorder (OUD)
treatments.
Background
When the CDC first approved opioids, doctors did not think they were addictive, so they
were prescribed in large quantities (CDC, 2018a). The national opioid use rate declined between
2012 and 2017. In 2017, the recommended prescription rate fell to 191 million prescriptions, or
58.7 prescriptions per 100 people (CDC, 2018a), a number last seen 10 years ago. Despite the
reduction in opioid prescriptions in 2017, prescription rates remained high in specific territories
across the nation. In 16% of U.S. districts, 100 opioid prescriptions per 100 people were written
(CDC, 2018a).
Physician-prescribed opioids, including heroin and synthetic opioids like fentanyl, have
caused approximately six times as many overdose deaths since 2000 (National Institute of Health
[NIH], 2020). Over 47,000 individuals in 2017 died due to opioid overdose, and over 35% of
those deaths were due to prescription opioids (CDC, 2018b). OUD is an enduring, long-term
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disease that can cause significant social, well-being, and financial issues. Opioids are a group of
medications that trigger feelings of pleasure and pain alleviation in the nervous system. Medical
providers may at times offer medically warranted opioid prescriptions to oversee acute and
persistent pain. Commonly used prescription opioids include oxycodone, fentanyl,
buprenorphine, methadone, oxymorphone, hydrocodone, codeine, and morphine. However,
heroin, which is an illicit drug, in commonly misused (NIH, 2020).
A propensity toward opioid dependence is described as a powerful, habitual desire to use
opioid medications, even when there is no therapeutical need (NIH, 2020). A certain individual
may be prone to opioid addiction even when taken as prescribed. Various solutions of opioids are
abused or misused or diverted to other individuals. It is undetermined why some individuals are
more probable to become dependent than others (NIH, 2020).
Opioids alter the brain’s chemicals by interfering with neurotransmitters, leading to
medication opposition, requiring an increase in dosage to achieve a comparative effect (NIH,
2017). Extended opioid use produces reliance. Significant reliance may result in physical
psychological signs and symptoms of withdrawal when individuals quit taking the medication.
Severely extended periods of opioid use may result in addiction. A small percentage may
encounter a compulsive need for the drug (NIH, 2020). OUD can cause serious medical issues,
as well as the risk of overdose. An overdose occurs when breathing slows or stops, causing
unconsciousness or even death without immediate attention. Either legal and illicit opioids pose a
possibility of overdose if used in irresponsible amounts or mixed with various medications,
particularly with a sedative known as benzodiazepine (NIH, 2020).
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Statement of the Problem
This project focused on evidence-based practice (EBP) for the effective treatment of
OUDs. According to the NIH, 128 opioid overdose victims die every day in the United States
(NIH, 2020). Opioid abuse and dependence, including narcotics, heroin, and synthetic opioids,
such as fentanyl, has become a major crisis that is also impacting public health and government
financial and social support. The CDC estimates that the total “financial burden” of OUD care in
the United States alone is over $75 billion per year, including the costs of medical services,
disabilities, treatment of predispositions, and illegal instructions and activities (NIH, 2020). In
2017, over 1.5 million people in the United States were diagnosed with opioid-induced OUD and
over 650,000 were diagnosed with heroin use disorders (NIH, 2020).
Economic Impact
OUD’s economic impact is a perpetuating crisis in the United States affecting individuals
across all age brackets, ethnicities, and communities. Medicaid is one primary health program
that contributes to OUD-related expenses. OUD patients require costly treatment assistance that
includes inpatient treatment, prescription medications, and ongoing required health care. The
average annual cost of medical treatment for OUD patients is over $75 billion (NIH, 2020). In
late 2018, the Health Resources Services Administration (HRSA) used over $350 million for
OUD and mental health patients in community health centers across the nation (HRSA, 2020).
Telehealth has facilitated providing the necessary care for patients struggling with OUD and
received a $700,000 grant to provide care to communities in need (HRSA, 2020). The societal
cost increased from $11 billion to $80 billion between 2001 and 2018 (Leslie et al., 2019). OUD
patients may also suffer from other comorbidities and require additional medical services. For
this reason, they are more likely to use the emergency room (ER) and be admitted to hospitals for
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more intensive care. OUD patients entering the ER have increased from a rate of nearly 10%,
and OUD deaths have increased to over 200% (Leslie et al., 2019). OUD individuals with
Medicaid are at increased risk of mental health issues and OUD compared to others.
Medicated-assisted treatment (MAT) for OUD consists of treatment using methadone,
buprenorphine, or naltrexone and behavior counseling. Naltrexone is administered orally or via
injection (NIDA, 2020). Over one-third of OUD patients are enrolled in the Medicaid program,
and the annual individual health care cost for OUD patients ranges from approximately $6,000 to
$15,000 and has continued to increase (NIDA, 2020).
Purpose of the Study
This descriptive and retrospective DNP project aimed to compare the efficacy of two
different adjuvant therapies in the treatment facility for OUD patients: (a) buprenorphine, and (b)
naltrexone Vivitrol (compound), naltrexone injection, extended-release, and Vivitrol injection. In
this study, I examined current practices for OUD treatment and the number of patients who
recovered during their stay. Patients with OUD receive care and support from nurses, doctors,
and social workers during their treatment. Specifically, they receive palliative care with MAT to
help patients recover from their addiction. MAT is the use of drug therapy in combination with
behavioral therapy to treat OUD and help people recover (FDA, 2020).
MAT has been effective in treating opioid use since the start of the OUD epidemic in the
United States. Every day, 128 people die from an overdose of OUD (CDC, 2018b). It’s a horrific
statistic that poses a huge challenge, but nurses must provide the care and resources they need to
save lives and produce positive results. MAT is one of the main strategies for the prevention,
intervention, and treatment of opioids. The FDA has approved three drugs to treat OUD:
buprenorphine, naltrexone, and methadone. Each of these treatments is safe and feasible when
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combined with behavioral therapy and support (FDA, 2020). Once the patient is discharged, they
must be continuously supported and treated externally to reduce the risk of recurrence.
Research Questions
RQ1: During inpatient MAT treatment for OUD, is there a difference between treatments
using buprenorphine/naloxone and those using Vivitrol in the length of stay of patients?
RQ2: Is there a difference in these two MAT (buprenorphine and Vivitrol) outcomes
when controlling for demographic variables of patients with OUD?
RQ3: Does ethnicity moderate the relationship in MAT types and the length of stay
among patients with OUD?
MAT is used to provide a holistic approach to the management of OUD treatment.
Studies show the combination of drugs and behavioral therapies can adequately address the
problem of substance abuse. MAT can help recovery (Substance Abuse and Mental Health
Service [SAMHSA], 2020b).
PICOT Question
For the study sample—adult patients with OUD—are there discernible differences in
efficacy across two different MATs, buprenorphine/naloxone and Vivitrol, toward sustaining
functional recovery (study outcome) over the length of stay (study timeframe)?
Significance of Problem
The importance of the descriptive, retrospective DNP project was its ability to identify
discernible differences in efficacy between two different MATs: (a) buprenorphine/naloxone
(consisting of buprenorphine, buprenorphine-naloxone, naloxone, and sublocade), and (b)
Vivitrol (consisting of naltrexone, naltrexone injection, extended-release, and Vivitrol injection)
over their length of stay to examine the complexity of opioid addiction that affects almost every
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aspect of an individuals’ life. The study was also important to address drug treatment program
issues, including offering solutions to ancillary problems.
One benefit of the proposed project is that the findings may offer insight on how to
sustain functional recovery in patients with OUD. Findings may also detail which treatment
therapies patients may benefit from most during and following inpatient treatment discharge.
Organizations that implement recommendations from the findings could benefit by
demonstrating the facility has a productive program with sustained functional recovery of OUD
patients throughout their length of stay. Results may equip nurses with tools, such as education
and training, to provide quality care for patients. Finally, society at large may benefit as insights
from study findings facilitate relationship building with patients’ families and help patients
become productive members of the community.
Definition of Key Terms
Dependence. Dependence refers to the need for something (Medical Dictionary, n.d.).
Drug. A drug is any substance that alters an organism’s physiological state or brain when
consumed (FDA, 2018).
Drug diversion. Drug diversion refers to the medical and legal issues of the trade-offs of
legally prescribed controlled substances between people who are legally prescribed and others
for illegal use (CDC, 2019).
Drug misuse/abuse. Drug misuse/abuse is defined as persistent, nontherapeutic
medication use with the exclusive goal to alter one’s disposition, influence, and condition of
consciousness or affect a bodily function (WHO, 2020).
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Drug withdrawal. Drug withdrawal is characterized by the emergence of symptoms
upon sudden stopping or abatement of administration of prescription or recreational medications
(Medical Dictionary, n.d.).
Medication-assisted treatment (MAT). MAT combines FDA-approved pharmaceutical
therapy with counseling and behavioral therapies to provide a “holistic patient” approach to the
treatment of substance-use disorders (SAMHSA, 2020b, para. 1). MAT combines FDA-approved
drugs with counseling and behavioral therapies to provide a “whole-patient” approach to
substance use disorder treatment (SAMHSA, 2020b, para. 1).
Opioids. Opioids are substances that act on opioid receptors in the body and are
primarily used to relieve pain and discomfort (CDC, 2020).
Pain. Pain refers to physical discomfort caused by illness or injury (Merriam-Webster,
n.d.).
Prescription. A prescription is an instruction written by a medical practitioner that
authorizes a patient’s use of medication for treatment (Merriam-Webster, n.d.).
Summary
The descriptive, retrospective study will focus on OUD patients that were initially
prescribed opioid therapeutically and eventually misused and became addicted while using an
opioid medication. Two different MATs (a) buprenorphine/naloxone (consisting of
buprenorphine, buprenorphine-naloxone, naloxone, and sublocade) and, (b) Vivitrol (consisting
of naltrexone, naltrexone injection, extended-release, and Vivitrol injection) were compared to
determine which sustained functional recovery most effectively over their length of stay. The
overall goal was to compare the effectiveness of these two MATs toward sustaining functional
recovery.
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Chapter 2: Literature Review
Restrictions on literature search apply to peer-reviewed articles, journals, publication
years 2016-2020, articles written in English, and studies conducted in the United States, London,
and the Ukraine only. Document searches were performed using the CDC, PubMed, Medline
Plus, Department of Health and Human Services, NIH, and Cochrane archives. The main terms
included in the literature search were: adults, buprenorphine, therapeutic uses, and healthcare
professionals, disorders/epidemiology, primary health care, behavioral health, behavioral
therapy, pain management, intervention, prescription, overdose, dependence, withdrawal,
prescribing, illegal, illicitly, manufactured, death, chronic disease, health, social-economic,
pain, health care providers, fentanyl, compulsive, characterized, medically, misused, diverted,
humans, injections, inpatient, statistics, numerical data, middle-aged, naltrexone, narcotic
antagonist, opioid-related disorders, outpatient, randomized controlled trials, recurrence, and
substance withdrawal syndrome.
The study recruited 58 opioid-dependent participants to undergo MAT with
buprenorphine (n = 26) or methadone (n = 32). The participants were recruited through local
advertising and gave written informed consent to the study site treatment center’s IRB-approved
protocol after the procedures were fully explained. MAT showed almost positive clinical
outcomes in terms of deaths from overdose, infectious disease, crime, and cultural background
when transitioning from opioid agonists to long-acting opioids buprenorphine and methadone,
but patients exacerbate the metabolic effects of methadone (Elman et al., 2020). In this study,
subjects with metabolic syndrome tended to be more severe. They found that it reduced the
craving for opiates and, unlike methadone, its role in metabolic disorders is unknown.
Researchers have discovered that the MAT-delivery process needs to be fine-tuned. In particular,

9
the discussion of informed consent before the implementation of treatment plans should take into
account the possibility of metabolic disorders. Researchers also emphasized the importance of
lifestyle changes, including diet and exercise (Elman et al., 2020). However, buprenorphine is
associated with a beneficial effect on reducing metabolic disputes and thirst, so the first step is to
discuss informed consent before doctors consider that agonist therapy is needed.
Based on the finding that maternal and paternal phenotypes are passed down from
generation to generation, this review shows that parental drug use history, especially the use of
new synthetic opioids (NSOs), has a significant impact on the next generation. Individuals can
develop OUD due to a family history of drug addiction. However, researchers have identified
some genetic variations associated with drug addiction, suggesting that genetics only partially
explains addiction (Gilardi et al., 2018). Researchers have found that opioid use affects the
opioid responsiveness of children and future generations, perhaps through epigenetic
mechanisms, even before conception. They found evidence that opioids can affect long-term
psychological effects, especially drug susceptibility, tolerance, and possible effects on vulnerable
drug abusers. The researchers warned that each clinical study has weaknesses that limit their
confidence in understanding the true impact of NSO transmission on future generations. Finally,
they recommended that future studies take into account maternal and maternal drug use patterns,
as genetic transmission also occurs through the germ cells of the mother organisms (Gilardi et
al., 2018).
In longitudinal studies, Hser et al. (2016) recruited 1,080 opiate-dependent participants in
seven U.S. treatment programs from 2006 to 2009 to compare the long-term outcomes of MAT
with buprenorphine (n = 630) or methadone (n = 450). The researchers found that there was no
difference in mortality between patients taking buprenorphine or methadone. In contrast, the
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prevalence of opioid use during follow-up of participants randomized to receive buprenorphine
was higher than that of methadone. They concluded that many patients with OUD both during
and outside of maintenance treatment performed better with the MAT maintenance. They
recommended focusing on the factors that contribute to drug withdrawal due to the concomitant
use of cocaine or other substances by the patient, inadequate dosage, concomitant psychological
or stress conditions, and unintentional cessation of drug use (i.e., strict clinical requirements)
(Hser et al., 2016).
Jarvis et al. (2018) conducted a systematic review and meta-analysis of three studies
published between 2006 and 2017 on the efficacy of naltrexone (XR-NTX) in the treatment of
opioid abuse/addiction. There were four research questions: (1) How successful have you been
with XR-NTX?, (2) What is the XR-NTX compliance rate?, (3) Does XR-NTX reduce opioid
use?, and (4) What are the factors associated with XR-NTX induction and adherence and opioid
use during XR-NTX treatment? According to Jarvis et al., successful treatment with XR-NTX
depends on two factors: initiation and continuation of the drug. Many people try to start XRNTX but fail to get started, and most people who start treatment with XR-NTX stop treatment
early (Jarvis et al., 2018). There were no significant differences in MAT results between doses of
XR-NTX, buprenorphine, or methadone. XRNTX reduced opioid use compared to a placebo in
Russian adults, but differences in retention between study groups confused this effect. XR-NTX
appears to reduce opioid use, but there is little experimental evidence for this effect (Jarvis et al.,
2018).
Klein and Seppala (2019) reported that MAT is proven to be effective due to the
philosophical contradictions offered by many US treatment programs, but most US drug
treatment providers do not use MAT. Klein and Seppala (2019) used a sample of 253 OUD
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patients to compare treatment results for buprenorphine/naloxone, oral naltrexone, and injectable
naltrexone. Patients posttreatment showed significantly higher withdrawal rates than those who
reported noncompliance. Postdischarge recurrence was not associated with substance use, and
adherence was primarily unrelated to changes in the frequency of alcohol or substance use. This
study has shown that it is useful to use drugs containing partial opioid agonists such as
buprenorphine as part of a 12-step treatment, and taking these drugs as prescribed gives good
results (Klein & Seppala, 2019).
In another study, 135 Ukrainian patients with OUD were enrolled, received monthly
injections of sustained-release naltrexone (XR-NTX), and were followed for three months
(Makarenkoa et al., 2019). In Ukraine, methadone or buprenorphine MAT is available for the
treatment of OUD, but the acceptability and scope of MAT remain low (Makarenkoa et al.,
2019). XR-NTX has recently become known as another treatment option in this area, and
researchers are trying to test its feasibility. Of the participants, 101 (75%) completed three 3
months of treatment (consecutive injections of XR-NTX), with a significant reduction in opioid
use from self-reported (67% to 22%) and urine drug testing (77% to 24%). However, alcohol,
marijuana, and stimulant consumption did not change (Makarenkoa et al., 2019). Drug cravings
and depressive symptoms also declined significantly, and health-related quality-of-life scores
improved over time. Researchers suggest that XR-NTX treatment results in a significant
reduction in opioid use and an improvement in quality of life, suggesting that XR-NTX treatment
is viable and well-tolerated in Ukraine for three months (Makarenkoa et al., 2019).
Oesterle et al. (2019) performed a brief review of the three major drugs approved by the
FDA and used to treat OUD. This examination contains a useful history of MATs that began in
the 19th century before investigating the historical background, benefits, challenges, and
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governance of each MAT. Next, the authors compared the three MATs and observed that
naltrexone has no real potential for addiction, but has compliance issues (Oesterle et al., 2019).
Buprenorphine is associated with higher adherence than naltrexone and has produced better
results. At constant doses (> 16 milligrams daily), adhesion/retention was similar to that of
methadone. However, its partial agonist properties also lead to potential abuse (Oesterle et al.,
2019). Although methadone shows the best therapeutic retention, its full agonistic properties
offer the greatest potential for abuse and are the most expensive to use (Oesterle et al., 2019).
Presnall et al. (2019) used Missouri Medicaid 2008-2015 data (7,606 claims) to estimate
the relative risk of missed buprenorphine-related treatments and hospital admissions in
psychosocial programs and care settings. They compared the results of OUD treatment with and
without buprenorphine with the results of buprenorphine treatment in the OUD psychosocial
programs, such as federally-approved medical centers, clinics, and facilities. They found that the
addition of MAT treatment with buprenorphine was associated with a significantly reduced risk
of discontinuation compared with psychosocial treatment without buprenorphine. The
researchers concluded that the use of buprenorphine in Medicaid treatment that included
psychosocial OUDs reduced patient referral and hospitalization rates (Presnall et al., 2019). In
addition, the clinic’s buprenorphine treatment reduced these side effects. They recommended
increasing access to buprenorphine in all settings, especially in outpatient medical settings, and
through Medicaid to maximize patient retention. The expansion of the facility-funded OUD
treatment network at the clinic would allow uninsured patients to access an expanded network of
providers serving Medicaid beneficiaries with disabilities (Presnall, et al., 2019).
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A 2018 London-based study consisted of thirty-six face-to-face, semi-structured
qualitative interviews with daily heroin users without any treatment for opioid use (n = 12), those
prescribed daily oral buprenorphine (n = 12), and those prescribed daily oral methadone (n = 12)
(Tompkins et al., 2019). Researchers investigated the willingness of opiate users to inject drugs
into long-term buprenorphine stores and the factors that influence their interests (Tompkins et
al., 2019). Researchers were primarily aware of the high levels of craving, but not all participants
were eager to receive buprenorphine in the depot, and five positive factors and one negative
factor impacted their craving: (a) it decreased their exposure to pharmacies and drug treatment
services, (b) their belief that depot could alleviate improper drug use and facilitate recovery, (c)
they perceived the efficacy of depot buprenorphine, (d) the length of time and dosage were
favorable of depot buprenorphine injections, (e) the administration of the depot buprenorphine
injection in a medical setting could occur, and (f) a negative factor contributing to their desire
was their perception of greater possible adverse events associated with depot buprenorphine
injection (Tompkins et al., 2019). They concluded that when opioid users agree to buprenorphine
treatment, they can reduce illicit drug use and promote recovery (Tompkins et al., 2019).
Researchers at West Virginia University School of Medicine and Psychiatry examined
the medical records of 100 patients to assess the differences between psychiatric and distant
disorder treatment programs. West Virginia University CRC Behavioral Medicine Psychiatry is
the largest mental health facility in West Virginia. The facility provides treatment for OUDs onsite and in remote psychiatric clinics. Treatment of OUDs was tested with three results: use of
other substances, median up to 30 and 90 consecutive days without supervised opioid use, and
opioid use retention after 90 and 365 days of treatment. (Zheng et al., 2017). The researchers
found no statistically significant difference in the use of the other substances after psychological
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interventions with buprenorphine MAT via video conferencing and face-to-face MAT treatment
(Zheng et al., 2017). This study provided important data on how alternative MAT procedures can
increase access to psychiatric services through telemedicine for people with limited access to
health care. Ultimately, researchers pointed out that not only “recovery is more than just
drinking,” but additional factors such as employment, relationships, marriage, and criminal
activity are important factors influencing the outcome of recovery (Zheng et al., 2017, p. 138).
The OUD death epidemic in the United States continues to surge (CDC, 2018b).
Approximately 750,000 individuals have succumbed to drug overdose since 1999 (WideRanging Online Data for Epidemiologic Research [Wonder], 2020). Two out of three of those
deaths were from opioids, specifically heroin, fentanyl, or by prescription (Wonder, 2020). In
2018, over 47,000 individuals overdosed on opioids, almost 70% of the total that died from a
drug overdose that year (Wilson et al., 2020).
Between 1999 and 2018, there were three waves of opioid overdose deaths of nearly
500,000 people (Wonder, 2020). The first increase in opioid overdose began in the early 1990s
and increased in late 1999 (CDC, 2011). The second wave occurred in 2010 when more people
died from a heroin overdose (Rudd et al., 2014). Finally, the highest number of fentanyl-related
deaths was in 2013 (Gladden et al., 2016). More recently, individuals have combined fentanyl
with heroin and cocaine (Drug Enforcement Agency, 2019).
According to the NIDA (2020), about one in 20 patients who enter the ER for a nonlethal
drug overdose die two days to one year after taking the drug. OUD treatment in the ER typically
continues after discharge to diminish opioid-related deaths (NIDA, 2020). For example, patients
are discharged with resources to follow up with outpatient or inpatient care; however, there is no
follow-up care for these individuals. Weiner et al. (2020) found a significant number of
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discharged OUD patients received hard copy resources containing information about drug
treatment facilities but did not receive direct follow-up care. Between 2011 and 2015, over
11,000 patients treated in a Massachusetts hospital died anywhere between two days to one year
from an overdose after treatment in an ER (Weiner et al., 2020). More specifically, close to 6%
of these patients succumbed to opioid overdose within one year of the visit. Over 125 patients
died within a month and 30 patients died within the first two days. The majority of these patients
died at home before help could arrive (Weiner et al., 2020).
Evidence shows patients require a MAT program once discharged from the ER. For
example, one study found patients without follow-up treatment after discharge from the ER had a
higher death rate. Weiner et al. (2020) insisted medical professionals must administer
buprenorphine to OUD patients to reduce the high death rate among patients discharged from the
ER. He also demonstrated interest in determining OUD patients’ survival rate given novel
treatment relative to leaving patients to their own devices upon discharge with a list of treatment
facility options (Weiner et al., 2020).
The literature review summarizes how MAT treatment is beneficial when patients
consistently follow MAT treatment guidelines. Additionally, a review of the literature answers
the research question of which MAT is used during inpatient treatment—
buprenorphine/naloxone or Vivitrol—contributes most to sustaining functional recovery over the
length of stay among patients with OUD? This study aimed to compare the efficacy of two
different MATs.
Limiters and Research Methods
Out of the total number of articles, 20 used survey methodology. All searches focused on
MAT and drug treatment facilities. There were 14 articles used and the CDC provided current
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guidelines for patient clinical practice, including assessments for all possible treatments and
dangers of and safety guidelines for discontinuing opioids (CDC, 2018a). The new guidelines
published in 2016 specify health care providers and their patients should weigh the risks of
opioid use for therapeutic purposes against the benefits before beginning an opioid regimen and
begin usage only when both parties fully comprehend the potential consequences (CDC, 2018a).
The Effect of Opioid Use Disorder Across Generations
OUD is growing in the United States, and knowledge and respect for the epidemiology of
OUD and risks and sequelae of OUD are crucial to decrease adverse outcomes and deaths. The
following studies were conducted as an evidenced-based approach, enabling health care
providers and nurses to implement preventative measures, treatments, and patient interventions
that may minimize overdoses (Green, 2017).
According to the SMHSA (2018b), approximately 5.1 million young adults aged 18-25
years (i.e., over 14% of the young adult population) battled a substance use disorder in 2017. In
2017, about 3.4 million adults ages 18 to 25 years consumed large amounts of alcohol, which
contributed to a disorder. Approximately two million young adults were diagnosed with an illicit
drug disorder in 2017 (7.3% of young U.S. adults). Finally, heroin use among young adults
between ages 18 and 25 years has doubled in the past decade.
Among adults between the ages of 26 and older in 2017, approximately 13 million battled
an OUD, which represents 6% of the total population of adults aged 26 and older (SAMHSA,
2018b). In 2017, over 10 million adults in the United States aged 26 and older suffered from an
alcohol use disorder, which represents 5% of the this population. Finally, about four million
adults aged 26 years and over were diagnosed with an OUD in 2017, or about 2% of the this
population).
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In 2017, among older adults aged 65 years and older, over 1 million battled OUD
(Bogunovic, 2012). In the same year, close to 1 million also suffered from alcohol disorder, with
two-thirds battling the disorder before age 65, and over 90,000 suffered from OUD (SMSHA,
2018a). Between 20% and 65% of elderly individuals suffering from OUD also suffer from
another mental health issue (Bogunovic, 2012).
Prevalence of Opioid Use Disorder
It is often challenging to select an effective treatment therapy for the patient. In the
United States, approximately two million individuals are faced with OUD issues (SAMHSA,
2020a). Among individuals with OUD, specifically concerning prescribed opioids, close to
600,000 OUD cases are associated with heroin use, which is not a prescribed medication
(National Academic Press, 2017). However, a considerable number of these individuals do not
receive the necessary treatment they need (Dunlap & Edlund, 2018). One treatment option for
OUD is MAT, including methadone, buprenorphine, and naltrexone. Alternatively, some
individuals with OUD receive behavioral health treatment only. Several studies in the health care
setting have found positive long-term effects of MAT and behavioral therapy on patient
outcomes (Dunlap & Edlund, 2018).
An assessment of the risks and benefits of MAT and behavioral therapy is an important
step in understanding which treatments would benefit patients most. Using MAT in combination
with behavioral therapy once discharged may decrease rates of readmission into treatment
facilities. Understanding outcomes related to MAT is crucial to identifying the most effective
postdischarge treatment approaches for patients. The health care professional or treatment site
may impact the patient’s response to treatment and determine lifelong treatment success (Dunlap
& Edlund, 2018).
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Research has shown a holistic approach to combining MAT with counseling and
behavioral therapy is effective for OUD patients (SAMHSA, 2020b). This combination may
sustain recovery postdischarge from treatment facilities. FDA-approved opioid treatment
medications include methadone, buprenorphine, and naltrexone (SAMHSA, 2018a).
Care After Inpatient Treatment
Patients commonly desire follow-up care. Health care workers and counselors, including
case managers, often collaborate to arrange follow-up care with MAT for continuous patient
support (Sharareh, et al., 2019). Sharareh and colleagues (2019) conducted a study with 372
English-speaking patients 18 years or older admitted for opioid detoxification during the
enlistment time frame. Participants completed a 15-minute meeting during which nontreatment
research staff directed evaluations. By the time the meeting began, individuals had been given an
opioid agonist (Sharareh, et al., 2019). However, patients were not given full contact with
treatment staff due to influence and so the opioid agonist was provided to them indirectly
through nontreatment research staff. Findings showed that during gentle detoxification, patients’
beliefs about prescriptions’ viability, security, and consistency with a drug-free lifestyle
facilitated their decision to choose MAT. Post-MAT treatment recovery choices contributed to
whether patients began MAT treatment after detoxification given that MAT was the patient’s
choice of treatment. Additionally, patients who chose to not receive MAT held the most
dissenting views toward MAT. Although many professionals in the healthcare setting play a role
in treatment initiation and post-detoxification treatment, attempts to develop MAT may be
beneficial if healthcare professionals provide continual care after discharge (Sharareh et al.,
2019).
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Miclette (2017) conducted a study involving collaboration between a group of
researchers, policymakers, and clinicians in addressing gaps in evidence-based opioid policy and
practice via the development of a medical design aimed to disrupt the OUD epidemic. Several
opioid overdose scenarios were considered to help delineate how to close the gaps in OUD
treatment, postdischarge follow-up care, and health care team coordination. All methods were
evidence-based to benefit OUD patients (Miclette, 2017). Collaborative team members
completed a survey assessing their perceptions of what would be most beneficial for the patients
at the end of the conference (Miclette, 2017). Survey findings revealed a total of four favorable
and attainable outcomes: (1) quality of care—payment rendered based on current evidence and
quality of care, abolish implications of order in prescribing buprenorphine, and create a selfsupporting accreditation organization with MAT facilities on quality of care and list other
agencies and quality ratings; (2) continuity of care— provide follow-up care led by the health
care team once the patient is discharged (e.g., discharge planner, peer groups, and MAT team),
ensure personal health care providers are affiliated with MAT, and ensure the local ER is
equipped to care for patients with OUD emergent conditions; (3) opioid prescribing and pain
management—request insurance companies find alternative methods to opioids for treating pain,
correlate prescription guidelines for federal funding, and hold state government agencies
accountable for opioid prescribing; and (4) facility engagement— provide a list of different
MAT facilities and providers and allow patients to choose where they want to go, allow family
and caregivers to be involved with care, have patients rate different MAT facilities, and find
ways to motivate individuals to seek treatment. Miclette (2017) stated findings fulfilled the shortterm goal of polling researchers, policymakers, and clinicians, and the long-term goal is to
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develop strategies in the prevention of prescription misuse and addiction to opioids (Miclette,
2017).
Summary
OUD deaths are an ongoing crisis in the United States (CDC, 2018b). According to the
CDC (2018b), an estimated 700,000 drug overdose-related deaths have occurred in the United
States between 2000 and 2017. Studies have shown MAT is effective in treating OUD since the
beginning of the epidemic in the United States (CDC, 2018c). MAT, the combination of
medication in conjunction with counseling and behavioral therapies, is one primary measure
taken for opioid abuse prevention, intervention, and treatment. Research has shown that MAT is
effective in the treatment of OUD and can assist individuals with recovery (FDA, 2020).
OUD treatment is an important topic for health care professionals in raising awareness of
the gravity of the OUD crisis in the United States. Participation in MAT-treatment approaches is
essential for addressing the OUD epidemic. MAT treatment is one approach that can be taken to
counteract the opioid crisis through comprehensive pain management techniques and
prescription monitoring remedies. Discussing the reasons individuals misuse and become
addicted to opioids is the first crucial step toward reducing the supply of and demand for opioids.
Preventative measures in the form of peer-group therapy or other interventions involving a
certified health care team must address risk factors and challenges with self-control to produce
cognitive and behavioral improvements in individuals with OUD (NIH, 2020). Significant
priority should be given to the discovery of how to implement evidence-supported opioid
prevention programs effectively. Historically, the high cost of interventions has been one barrier
to their implementation (NIH, 2020).
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Chapter 3: Research Method
This chapter reviews the research methodology used for this DNP project. A review of
the methodology includes a discussion of the research approach, research strategies for data
collection, sample selection, research process, data analysis procedures, ethical considerations,
and research limitations. The purpose of this research was to test whether there were significant
differences in the effectiveness of two different MATs in an inpatient facility. Participants were
inpatient, male and female OUD patients aged 18 and older. Findings from this project may
provide new insight on the sustainability of patients’ functional recovery while in inpatient
facilities and aid understanding on why patients relapse and return to drug treatment facilities.
Project Design
The project used a retrospective design looking at the types of therapies offered in
inpatient care, which included computer data on the treatment practice used for OUD patients
over the two years. The data were collected by the study site’s vice president of operations from
a preexisting database for 2019 and 2020 from their business intelligence office. The staff at the
patient intake departments collected the original data. Due to the COVID-19 pandemic, I was
unable to collect data myself. The research only involved the collection and analysis of
identifiable health information to determine if there were discernable differences in efficacy
when comparing two medication assistant therapies (buprenorphine and Vivitrol) toward
sustaining functional recovery over their length of stay. The human subjects were inpatient OUD
patients from the age of eighteen and older, male and female, and included all ethnicities. The
retrospective study held concerning this project provides new information on patients admitted to
drug treatment inpatient facilities. This project assisted in determining if there were discernible
differences in efficacy when comparing two different MATs, buprenorphine/naloxone
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(consisting of buprenorphine, buprenorphine-naloxone, naloxone, and sublocade) and Vivitrol
(consisting of naltrexone, naltrexone injection, extended-release, and Vivitrol injection) toward
sustaining functional recovery over the patients’ length of stay. The drug treatment facility
located in the Western New York State area is a 28-bed inpatient detoxification facility and 40
beds are termed crisis—often, patients move from detox to crisis stabilization to residential
rehabilitation within 24-hours. The health care team consisted of physicians, nurses, licensed
counselors, peer support, and discharge planners. This project looked at the types of therapies
offered in an inpatient setting.
The participants were only identified by demographic and health information. There was
no physical contact with the patients, and all were de-identified throughout the study. I
investigated the frequencies of the demographic variables. I first conducted descriptive analyses
for study variable characteristics, such as means, SDs, skewness, and kurtosis to evaluate the
normality of the dependent variable and the continuous covariant of age. Also, I collected data
on the length of stay of each participant. The second step of my preliminary analyses was to
conduct assumptions tests to ensure ANCOVA assumptions were not violated. I conducted three
separate tests of normality to address RQs 2 and 3 only. For homoscedasticity, I created a
scatterplot of the standardized residual against the unstandardized predicted values of length of
stay. I also tested the normality of residuals and created a normal Q-Q plot of the standardized
residuals and homogeneity (equality) of variables and then conducted a Levene’s test. The pvalue must be over 0.5 (Levene, 1960).
RQ1: During inpatient MAT treatment for OUD, is there a difference between treatments
using buprenorphine/naloxone and those using Vivitrol in the length of stay of patients?
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RQ2: Is there a difference in these two MAT (buprenorphine and Vivitrol) outcomes
when controlling for demographic variables of patients with OUD?
RQ3: Does ethnicity moderate the relationship in MAT types and the length of stay
among patients with OUD?
The primary analysis for hypotheses H1, H2, and H3 was as follows:
H1: The independent sample t-test in which the MAT type was the predictor variable and
the length of stay was the dependent variable.
H2: ANCOVA covariance with MAT type as the predictor, controlled for age,
employment, sex, living arrangements, ethnicity, DX type, and year collected.
H3: ANCOVA analysis covariance with MAT type as the predictor, controlled for age,
employment, sex, living arrangements, ethnicity, DX type, and year collected and ran interaction
between MAT type and ethnicity.
Summary
Planning and the dedicated assistance from the vice president of operations at the facility
in which I conducted the study assisted me with this DNP project. The findings from the data
were important and relevant in providing MAT treatment for individuals suffering from OUD.
Increasing the awareness of OUD along with continual training and education for healthcare
professionals, patients, and their families will decrease the many barriers of evidence-based
practice, which in this case provides a better outcome for patients suffering from OUD. In
fulfilling the project objectives, the retrospective study was beneficial in obtaining information
from the facility the provides MAT for individuals suffering from OUD.
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Chapter 4: Results
Preliminary Analyses
Of the 433 participants, the majority were male (60%; see Table 1). Most participants
were White (n = 367, 84.8%) and not Hispanic (n = 407, 94%). Over half of the participants
lived with a spouse or relative (n = 254, 58.7%) and all remaining participants either lived with a
nonrelative (n = 103, 23.8%) or alone (n = 76, 17.6%). Two-thirds of the sample were
unemployed (n = 287, 66.3%). Individuals in the analysis had mild, moderate, or severe OUD,
and most had severe cases as defined by the DSM diagnosis (n = 292, 67.4%), and of the 433
participants, 78 were given some kind of buprenorphine, and 36 were given Vivitrol.
Descriptives for categorical study variables are illustrated in Table 1, and descriptives for
continuous study variables are shown in Table 2. Both lengths of stay and age were normally
distributed.
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Table 1
Frequencies of Categorical Study Variables
Variable
Gender

Race

Ethnicity

Living
arrangement

Employment

DSM
disorder

MAT type

Year
collected

Male
Female
Total
White
Black
Other
Total
Not Hispanic
Hispanic
Missing
Total

N
260
173
433
367
33
33
433
407
22
4
433

%
60.0
40.0
100.0
84.8
7.6
7.6
100.0
94.0
5.1
0.9
100.0

Alone
Spouse/Relatives
Non-relative
Total
Unemployed
Employed
Missing
Total

76
254
103
433
287
105
41
433

17.6
58.7
23.8
100.0
66.3
24.2
9.5
100.0

Mild
Moderate
Severe
Total
Buprenorphine/Naloxone
Vivitrol
Missing
Total

88
53
292
433
78
36
319
433

20.3
12.2
67.4
100.0
18.0
8.3
73.7
100.0

2019
2020
Total

230
203
433

53.1
46.9
100.0
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Table 2
Descriptives for Continuous Study Variables
Variable
Length stay
Age

N

Min

Max

M

SD

433
433

0
20

1228
63

160.24
34.94

196.44
8.64

Skewness
Stat
SE
2.14
0.12
0.88
0.12

Kurtosis
Stat
SE
5.79
0.23
0.37
0.23

I first conducted assumptions of analysis of covariance (ANCOVA) to address RQ2.
First, tests for homoscedasticity produced a scatterplot of standardized residuals against
unstandardized predicted values of length of stay. A visual inspection of the scatterplot showed
variance was equal for all values of the length of stay (see Figure 1).
Figure 1
Scatterplot of Standardized Residuals Against the Unstandardized Predicted Values for RQ2

Second, a normal Q-Q plot of the standardized residuals was created from the ANCOVA
analysis to test the normality of residuals. A visual inspection of the Q-Q plot showed the
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assumption of normality was not violated as residuals were normally distributed (see Figure 2).
Third, I conducted a Levene’s test for equality of variances to test for the homogeneity of
variances. The assumption of homogeneity of variances was not violated (p = .71).
Figure 2
Normal Q-Q Plot of Standardized Residuals for Regression Analysis for RQ2

Several steps were taken to test assumptions for three-way ANCOVA to address RQ3.
First, a test of homoscedasticity was conducted via a scatterplot of standardized residuals plotted
against unstandardized predicted values of length of stay. A visual inspection of the scatterplot
showed variance was equal for all values of the predicted dependent variable (see Figure 3).
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Figure 3
Scatterplot of Standardized Residuals Against the Unstandardized Predicted Values for RQ3

Second, a test of the normality of residuals was conducted. A normal Q-Q plot of
standardized residuals from ANCOVA analysis was generated. A visual inspection of the Q-Q
plot showed the assumption of normality was not violated (see Figure 4) as residuals were
normally distributed. Third, I conducted a Levene’s test of equality of variances to test the
homogeneity of variances. The assumption of homogeneity of variances was not violated (p =
.78).
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Figure 4
Normal Q-Q Plot of Standardized Residuals for Regression Analysis for RQ3

Primary Analyses
Hypothesis 1 posited there would be a difference in length of stay between groups
receiving buprenorphine/naloxone compared to Vivitrol.
•

Null Hypothesis: There is no significant difference in length of stay between the two
MAT types.

•

Alternative Hypothesis: There is a significant difference in length of stay between the
two MAT types. Buprenorphine would have a shorter length of stay compared to
Vivitrol when controlling for length of stay.

RQ1: During inpatient MAT treatment for OUD, is there a difference between treatments
using buprenorphine/naloxone and those using Vivitrol in the length of stay of patients?
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H01: There will be no significant differences in length of stay between groups receiving
two MAT types: buprenorphine/Naloxone and Vivitrol.
Ha1: There will be a significant difference in length of stay between
buprenorphine/Naloxone and Vivitrol.
To test this hypothesis, I conducted an independent samples t-test with the length of stay
as the dependent variable and MAT type as the grouping variable. Levene’s test for equality of
variances was conducted to examine whether variances in the dependent variable were equal in
both groups based on MAT type. Because the assumption of homogeneity of variances was not
violated (p = .50), a correction was not needed. Participants administered some form of
buprenorphine (M = 252.60, SD = 200.16) did not stay significantly longer than participants
administered Vivitrol (M = 273.25, SD = 241.47; t(112) = -0.48, p = .63, Cohen’s d = -.10).
Hypothesis 2 posited there would be a difference in the average length of stay between MAT
groups when controlling for demographic variables (i.e., age, employment status, sex, race,
ethnicity, living arrangement, DSM disorder, year data was collected).
RQ2: Is there a difference in these two MAT (buprenorphine and Vivitrol) outcomes
when controlling for demographic variables of patients with OUD?
H02: There is not a significant difference in the average length of stay between MAT
groups when controlling for demographic variables.
Ha2: Alternative hypothesis: There is a significant difference in the average length of stay
between MAT groups when controlling for demographic variables. Buprenorphine would have a
shorter length of stay compared to Vivitrol when controlling for length of stay.
To test this hypothesis, I conducted an ANCOVA predicting length of stay from MAT
type controlling for demographic variables. First, it is important to mention demographic
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variables did not significantly predict the length of stay (see Table 3). The overall model did not
account for significant variation in length of stay (F(12, 94) = .67, p = .78, partial η2 = .08).
Additionally, MAT type did not significantly predict length of stay when controlling for
demographic predictors (F(1, 94) = 0.02, p = .97, partial η2 = .00.
Table 3
Between-Subjects Effects of Predictors for RQ2
Model 1
Corrected Model
Intercept
Age
Living
Employment
DSMVDx
Sex01
Race
Ethnicity
MAT
Year
Error
Total

Type III SS
322577.61
102306.67
2696.53
57214.37
11250.29
140609.14
43030.54
22446.74
6040.96
71.89
14712.46
3769194.75
10432878.00

df
12
1
1
2
1
2
1
2
1
1
1
94
107

MS
26881.47
102306.67
2696.53
28607.18
11250.29
70304.57
43030.54
11223.37
6040.96
71.89
14712.46
40097.82

F
0.67
2.55
0.07
0.71
0.28
1.75
1.07
0.28
0.15
0.00
0.37

p
0.78
0.11
0.80
0.49
0.60
0.18
0.30
0.76
0.70
0.97
0.55

Partial η2
0.08
0.03
0.00
0.02
0.00
0.04
0.01
0.01
0.00
0.00
0.00

Hypothesis 3 posited that ethnicity would change the relationship between MAT type and
length of stay when controlling for demographic variables (i.e., age, employment status, sex,
race, race, living arrangement, DSM diagnosis, year data was collected). This was a moderation
analysis that was intended to test ethnicity as a moderator on the relationship between MAT
treatment and length of stay. My prediction was that I did not think that ethnicity would change
the relationship between MAT type and length of stay when controlling for demographic
variables. I predicted that all ethnicities (Hispanic and Non-Hispanic) that were being
administered buprenorphine would have a shorter stay, because buprenorphine is an opioid
agonist and protects against overdose, which decrease the chances of death. Vivitrol is an
extended-release opioid agonist that is administered as a monthly injection.
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RQ3: Does ethnicity moderate the relationship in MAT types and the length of stay
among patients with OUD?
H03: Ethnicity does not change the relationship between MAT type and length of stay
when controlling for demographic variables.
Ha3: Ethnicity does change the relationship between MAT type and length of stay when
controlling for demographic variables. Non-Hispanics taking buprenorphine had the shortest
length of stay.
To test this hypothesis, I conducted a three-way ANCOVA. First, two MAT treatment
levels (i.e., buprenorphine/naloxone (consisting of buprenorphine, buprenorphine-naloxone,
naloxone, and sublocade) and, (b) Vivitrol (consisting of naltrexone, naltrexone injection,
extended-release, and Vivitrol injection), and two ethnicity levels (i.e., Hispanic and NonHispanic) were entered into the model as independent variables. Second, an interaction term
between ethnicity and MAT treatment levels was created and entered into the model. Third,
length of stay was entered as the dependent variable. Finally, demographic variables were
entered as control variables including age, employment status, sex, race, living arrangement,
opioid use severity and year collected.
The overall model did not account for significant variation in length of stay (F(13, 93) =
.66, p = 0.80, partial η2 = 0.08). Ethnicity did not moderate the relationship between MAT type
and length of stay (F(1, 93) = .51, p = .91, partial η2 = .001; see Table 4).
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Table 4
Between-Subjects Effects of Predictors for RQ3
Model 1
Corrected Model
Intercept
Age
Living
Employment
DSMVDx
Sex01
Race
Ethnicity
MAT
Year
Ethnicity*MAT
Error
Total

Type III SS
343148.19
89060.25
5369.40
54701.48
17681.29
156105.48
41405.91
7706.40
2822.42
16991.61
15494.53
20570.59
3748624.16
10432878.00

df
13
1
1
2
1
2
1
2
1
1
1
1
93
107

MS
26396.02
89060.25
5369.40
27350.74
17681.29
78052.74
41405.91
3853.20
2822.42
16991.61
15494.53
20570.59
40307.79

F
0.66
2.21
0.13
0.68
0.44
1.94
1.03
0.10
0.07
0.42
0.38
0.51

p
.80
.14
.72
.51
.51
.15
.31
.91
.79
.52
.54
.48

Partial η2
0.08
0.02
0.00
0.01
0.01
0.04
0.01
0.00
0.00
0.01
0.00
0.01
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Chapter 5: Discussion, Conclusions, and Recommendations
The purpose of this study was to examine current practice for OUD treatment and
investigate if there was a difference in MAT treatments (buprenorphine/naloxone and Vivitrol)
based on demographic variables, ethnicity, and the length of stay among patients with OUD.
This chapter presents a discussion of the findings based on differences in the length of stay
between two different MATs in an inpatient drug treatment facility for individuals with OUD: (a)
buprenorphine/naloxone (consisting of buprenorphine, buprenorphine-naloxone, naloxone, and
sublocade) and, (b) Vivitrol (consisting of naltrexone, naltrexone injection, extended-release, and
Vivitrol injection).
Study findings showed that of the 433 total participants in the study, 114 received some
type of MAT treatment. Most of these participants were White, non-Hispanic men. Over half of
the participants lived with family and the other half lived with nonrelatives. Two-thirds of
participants were unemployed, and most of them suffered from a DSM diagnosis. Of the 433
participants, 78 were administered some kind of buprenorphine, and 36 were administered
Vivitrol. Length of stay and age were both normally distributed (see Table 1).
Recommendations
The recommendations for future research would be to improve the education and training
for healthcare professionals about providing MATs to OUD patients, finding the benefits, and
how to provide follow-up treatment for medication and behavioral health compliance. In the case
of COVID or if another pandemic arises, medical professionals should be equipped with the
resources that could benefit individuals suffering from OUD, their mental or behavioral health
issues, and the medical services they are provided. Another recommendation would be to
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conduct a qualitative study so that researchers could have physical contact with the patients and
staff for interviews, interaction, and observe how services are provided.
The finding that there is no significant difference in length of stay between two MAT
types buprenorphine and Vivitrol is consistent with previous work. According to Klein and
Seppala (2019), patients in treatment programs initiated in a residential or day treatment setting
with outpatient follow-up (one and six months) who reported compliance with their medicines
following treatment had significantly higher abstinence rates than patients who reported
noncompliance. Postdischarge relapse was associated neither with medication use nor was
compliance primarily related to a change in the frequency of alcohol or drug use. The research
concluded that it is beneficial to administer medications, including partial opioid agonists like
buprenorphine, within the context of program-based treatment, and taking these medications as
prescribed is associated with favorable outcomes (Klein, & Seppala, 2019).
The finding that there is no difference in the average length of stay between MAT groups
when controlling for demographic variables is also consistent with past work. It is consistent
because, according to Presnall et al. (2019), buprenorphine treatment in office-based medical
settings was even more effective in reducing these adverse outcomes. They recommended
expanding access to buprenorphine in all environments, but particularly in office-based medical
settings and through Medicaid for the best potential for patient retention. Expansion of the grantfunded OUD treatment network to office-based medical settings would give uninsured patients
access to the growing network of office-based providers that serve Medicaid beneficiaries
(Presnall et al., 2019).
Because some researchers have demonstrated that ethnicity does change the relationship
between MAT type and length of stay when controlling for demographic variables, my findings
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were inconsistent with past work According to Stahler & Mennis (2018), it was found through
data obtained from the Treatment Episode Dataset-Discharges (TEDS-D) regarding geographical
variations and ethnicity to see if they played a role in completing inpatient MAT treatment with
individuals with OUD. It was found that 28% of clients were successful in completing the
treatment and that among those clients, Hispanics were less likely to complete the treatment
(Stahler & Mennis, 2018). The study also found that there is a need for improving inpatient
treatment for those that have medical needs in smaller geographical areas (Stahler & Mennis,
2018).
Limitations
There were some limitations while trying to research my DNP project. One of the main
obstacles was COVID-19. COVID-19 prohibited me from actually going to the facility to
physically meet the healthcare professionals and faculty that provide such dedicated care for
these individuals suffering from OUD. In addition, this was not a true experiment, because I
could not randomly assign who received which type of medication, so I cannot establish
causality as it might have been that certain factors necessitated some patients to have one type of
treatment over the other. This prohibited me from finding what I predicted. Because of the
limited sample size of some of the MAT subtypes, I was unable to test differences between the
types of administration for buprenorphine, which may have also made it harder for my
prediction.
Conclusion
OUD continues to be an epidemic in the United States and a total of 128 victims continue
to die daily due to opioid overdose (NIH, 2020). The abuse of and reliance on opioids, including
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pain relievers, heroin, and synthetic opioids (e.g., fentanyl), is a severe crisis impacting public
health and social and financial government assistance equally.
OUD facilities continue to provide effective treatment for individuals that suffer from
OUD. One treatment commonly used for individuals with OUD used is MAT: (a)
buprenorphine/naloxone and (b) extended-release naltrexone (Vivitrol). MAT is used to assist
patients in the addiction recovery process. MAT is the use of medications in conjunction with
counseling and behavioral therapies and is powerful for treating OUD and assisting individuals
with recovery (FDA, 2020).
This DNP project focused on the number of patients who sustained recovery across their
length of stay. The director of the facility where I conducted the research expressed her interest
in and dedication to alleviating this epidemic, and thus offered support for the project to improve
the services they provide to the individuals they serve. The role of the team members (i.e.,
nurses, physicians, counselors) fighting OUD is tremendously complex. The ability to implement
the MAT program and experience the benefits is rewarding to the health care team, the patients,
and their families. Further education is needed to assist in the fight against this deadly epidemic.
EBP Findings and Relationship to DNP Essentials 1–8
Upon completing this doctorate project, it revealed the competence of the eight DNP
Essentials for advanced practice nursing. This section conveys the EBP of meeting each of the
eight essentials according to the Essentials of Doctoral Education for Advanced Nursing Practice
(American Association of Colleges of Nursing, 2006).
Essential I: Scientific Underpinnings for Practice
A retrospective study based on the scientific underpinnings supported this DNP project’s
preparation, implementation, and analysis. The retrospective study explored the roles of
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physicians, nurses, behavioral therapists, peer support specialists, and discharge planners in the
techniques, research approach, and strategies that provided new insight into patients’ functional
recovery sustainability while in inpatient facilities and understanding why patients relapse and
return to drug treatment facilities.
Essential II: Organization and Systems Leadership for Quality Improvement and Systems
Thinking
This study analyzed the different lengths of stay between groups of patients with OUD
receiving oral buprenorphine, subcutaneous buprenorphine, and Vivitrol in the treatment facility,
and the number of patients who sustain recovery during their length of stay. I collaborated with
the senior vice president of operations to obtain my information. She was there to answer any
questions I had because they were interested in treating OUD and providing patient care and
support within the organization. I obtained IRB approval from the organization and Abilene
Christian University.
Essential III: Clinical Scholarship and Analytical Methods for Evidence-Based Practice
In the literature review, I compared current practices and research into medication
regimes and lengths of stay within a treatment facility with patients with OUD. Research for this
DNP project showed it to be an evidence-based intervention to increase knowledge of the
effectiveness of the MAT program. Using this study’s methodologies and data analysis, clinical
competence in evaluating MAT is evidence-based.
Essential IV: Information Systems/Technology and Patient Care Technology for the
Improvement andTtransformation of Health Care
Retrospective data was utilized and evaluated to analyze patients’ quality of care through
the MAT treatment program and its effectiveness compared with the OUD patients length of stay
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for treatment. Having the ability to obtain information from a technological system and analyze
it for the competence of OUD treatment demonstrates competence in meeting DNP Essential IV.
Essential V: Health Care Policy and Advocacy in Health Care
While completing this DNP project, I had to understand that the OUD population is a
protected population. According to federal disability law, individuals addicted to opioids fall
under Section 504 of the Rehabilitation Act, the Americans with Disabilities Act, and Section
1557 of the Affordable Care Act (HHS, 2018). MAT is also included in this federal law because
MAT is administered under the supervision of a health care professional.
Essential VI: Interprofessional Collaboration for Improving Patient and Population Health
Outcomes
This DNP project required effective interprofessional communication and collaboration
in helping patients with OUD have better health outcomes. Meeting with the vice president of the
organization via Zoom was effective. Collaborating and understanding the implementation
process for the use of MAT through continued education for quality patient care was also
effective.
Essential VII: Clinical Prevention and Population Health for Improving the Nation’s Health
This DNP project required the need for and understanding of evidence-based guidance
for OUD and MAT treatment to provide quality patient care with those suffering from OUD. An
analysis of the increasing OUD deaths is causing an impact on society, so there is a need to gain
knowledge regarding preventative treatments for OUD.
Essential VIII: Advanced Nursing Practice
Through research and education, I implemented this DNP project. The MAT treatment
facility is supportive in achieving its excellence in OUD and providing treatment for those in
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need of assistance. Their knowledge of MAT treatment has raised the standards of healthcare
professionals and leaders for better patient outcomes.
Again, OUD continues to be an epidemic in the United States victims dying daily due to
opioid overdose (NIH, 2020). As a healthcare professional that has encountered this epidemic on
a personal and professional level, I feel that my role is to continue to find evidence-based
information to assist in fighting this crisis.
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Appendix A: Death Statistics
Figure A1
Overdose Death Rates Involving Opioids, by Type in the United States Between 1999 and 2018

Note. Adapted from Center for Disease Control and Prevention, by the National Center for
Health Statistics, 2020 (https://www.cdc.gov/nchs/data/databriefs/db356-h.pdf). In the public
domain.
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Figure A2
12 Month-Ending Provisional Number of Drug Overdose Deaths

Note. Adapted from Center for Disease Control and Prevention, by the National Center for
Health Statistics, 2020 (https://www.cdc.gov/nchs/health_policy/Provisional-Drug-OverdoseDeaths-Counts-and-Rates-by-County-2019.pdf). In the public domain.
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Appendix B: Project Timeline and Task List
Table B1
Project Timeline and Task List
January
February-March
April
May - July
August - September
October-November
December

Met with VP of Operations at treatment facility and
they accept me to research Project
IRB Approved / Received Data Sets
Revised Research Questions/
Focused on Literature Review
Data Analysis is Complete
Final Defense
Final Editing/Submit project for Publishing/
Editorial Review
Graduation
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Task

Met with VP of Operations at treatment facility
and they accept me to research project
IRB Approved / Received data sets
Revised research questions
Focused on Literature Review
Data analysis completed and
charts and grids made and
added to DNP project
Final Defense
Final editing /submit the project for
publishing
Editorial review
Graduation

Jan.

Feb.

Mar.

April

May

June

July

Aug.

Sept.

Oct.

Nov.

Dec.
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